Bioventus Inc. (NASDAQ:BVS – Get Free Report) has been given an average rating of “Moderate Buy” by the six ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $16.60.
BVS has been the subject of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 target price on shares of Bioventus in a report on Monday, August 17th. Canaccord Genuity Group lowered their price target on shares of Bioventus from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, November 3rd. Barrington Research set a $18.00 price target on shares of Bioventus in a report on Thursday, August 6th. Wall Street Zen lowered shares of Bioventus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 7th. Finally, Weiss Ratings cut shares of Bioventus from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, November 4th.
View Our Latest Report on Bioventus
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. grew its holdings in shares of Bioventus by 28.0% in the third quarter. Goldman Sachs Group Inc. now owns 835,154 shares of the company’s stock valued at $11,383,000 after purchasing an additional 182,787 shares in the last quarter. EP Wealth Advisors LLC bought a new stake in Bioventus in the third quarter worth $243,000. Pathstone Holdings LLC purchased a new stake in Bioventus during the third quarter valued at $199,000. Marshall Wace LLP purchased a new stake in Bioventus during the third quarter valued at $1,403,000. Finally, Nantahala Capital Management LLC raised its stake in Bioventus by 7.0% during the third quarter. Nantahala Capital Management LLC now owns 6,420,884 shares of the company’s stock valued at $87,517,000 after purchasing an additional 420,605 shares in the last quarter. Institutional investors own 62.94% of the company’s stock.
Bioventus Trading Down 1.9%
NASDAQ BVS opened at $10.46 on Tuesday. Bioventus has a 12 month low of $6.47 and a 12 month high of $15.89. The stock has a market cap of $881.37 million, a P/E ratio of 13.08, a P/E/G ratio of 1.39 and a beta of 0.66. The stock’s fifty day moving average price is $13.06 and its 200-day moving average price is $11.05. The company has a current ratio of 1.68, a quick ratio of 1.16 and a debt-to-equity ratio of 0.72.
Bioventus (NASDAQ:BVS – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The company reported $0.17 earnings per share for the quarter, meeting the consensus estimate of $0.17. Bioventus had a net margin of 9.78% and a return on equity of 26.31%. The firm had revenue of $142.44 million during the quarter. As a group, equities analysts forecast that Bioventus will post 0.78 EPS for the current fiscal year.
Bioventus Company Profile
Bioventus Inc. is a medical technology company focused on helping patients recover from musculoskeletal conditions and injuries. Its products and services support bone healing, pain management and surgical care. The company’s offerings include noninvasive devices that use ultrasound to support bone healing, injectable treatments for osteoarthritis pain, and surgical products such as bone graft materials and ultrasonic instruments used in procedures. Bioventus began operations in 2012, originating from businesses previously owned by Smith & Nephew.
Further Reading
- Five stocks we like better than Bioventus
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
